From scientific discoveries to promising clinical trials, City of Hope constantly advances new and better ways to improve the lives of people here and throughout the world.
You can find the latest information on our research, clinical and educational programs through this listing of current press releases.
City of Hope patients whose acute myeloid leukemia (AML) was no longer responding to standard therapies and a patient with a rare blood cancer, blastic plasmacytoid dendritic cell neoplasm, achieved a complete response (cancer-free) after undergoing treatment with CAR T cell therapy.
Research on the link between weight and breast cancer risk in postmenopausal women will be presented by a City of Hope researcher at the 2017 San Antonio Breast Cancer Symposium, held Dec. 5-9.
Research about clinical trials that lay the groundwork for novel non-Hodgkin lymphoma, acute myeloid leukemia and two rare blood cancers, myelofibrosis and blastic plasmacytoid dendritic cell neoplasm (BPDCN), will be among the highlights of the annual meeting of the American Society of Hematology (ASH) in Atlanta, Dec. 9 to 12.
Eleven patients and Dodger outfielder Enrique “Kike” Hernandez share how City of Hope is “Making A Difference” in their lives
City of Hope today announced that it has appointed Michael A. Caligiuri, M.D., in a new executive leadership role as president of City of Hope National Medical Center and physician-in-chief. Caligiuri is a health care visionary, world-renowned cancer researcher and president of the American Association for Cancer Research. He will join City of Hope in February 2018.
American and Israeli cancer scientists and physicians will meet at City of Hope on Friday, Nov. 10, to share the latest developments in collaborative research projects as part of the inaugural Jacki and Bruce Barron Cancer Research Scholars’ Program Symposium.
City of Hope announced today that it will present data on an abstract titled “Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial” at the American Society of Hematology Annual Meeting Dec. 9 to 12, 2017, at the Georgia World Congress Center in Atlanta.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will be one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration (FDA) announced today is the first approved CAR T cell therapy for adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. This is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL).
George Somlo, M.D., an internationally known breast cancer and hematology researcher at City of Hope, has been named director of pharmaceutical initiatives at the institution.